Trinomab(Zhuhai)'s last reported valuation, Jun 2025. Nothing priced has surfaced since.
- ·The complete investor list: 27 names
- ·Watch Trinomab(Zhuhai): the Monday email on marks, rounds and moves
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Trinomab(Zhuhai) funding history
No funding rounds for Trinomab(Zhuhai) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Trinomab(Zhuhai) valuation
Trinomab(Zhuhai)'s last reported valuation was $534 million in Jun 2025. No priced round, secondary trade or fund mark has surfaced since.
How Trinomab(Zhuhai)'s valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Trinomab(Zhuhai), the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →
Frequently asked about Trinomab(Zhuhai)
- What is Trinomab(Zhuhai) worth?
- Trinomab(Zhuhai) is valued at $533.7M as of Oct 2026. Trinomab(Zhuhai)'s last reported valuation, Jun 2025. Nothing priced has surfaced since.
- How much has Trinomab(Zhuhai) raised?
- Trinomab(Zhuhai) has raised $221.2M in total funding across its recorded rounds.